Two groups of patients with gastro-intestinal (GI) tumours (41) and recurrent glioblastoma (GBM), (17) underwent radioimmunotherapy after the failure of traditional treatments. A number of different MAbs were employed (anti-CEA and anti-Tenascin) which were labelled with I-131. The radiopharmaceuticals were administered by the intraperitoneal and intratumoral routes. As a rule the cycles were repeated to enhance the effectiveness of RIT. No significant early or late adverse effects were recorded. HAMA development was observed in all GI cases but only in a few GBM patients. The cumulative dose delivered to the target tumors was considerable (mean 8,900 cGy) in the GI group, and was much higher in the GBM patients (mean 51,700 cGy) owing to the particular modality of injection. Survival improved in both series of patients. The objective responses to RIT were promising: in the GI group 10 complete remissions (CR) and 6 partial remissions (PR) were observed, while in the GBM group 3 long-lasting CRs and 3 prolonged PRs were documented.
DouglasH.O.Jr., Gastric cancer: overview of current therapies.Semin Oncol1985; 12(Suppl 4): 57–62.
2.
SugarbakerP.H., GendersonL.L., WittesR.E.Colorectal cancer. In: De vitaV.T.Jr., HellmanS., RosenbergS.A., eds. Cancer: Principles and practice of oncology. Vol I, 2nd ed.Philadelphia: Lippincott1985; 795–866.
3.
ChangC.H., HortonJ., SchoenfeldD., SalazerO., Perez-TamayoR., KramerS., WeinsteinA., NelsonJ.S., TsukadaY.Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas.Cancer1983; 52: 997–1007.
De NardoS.J., De NardoG.L., O'GradyL.F., LevyN.B., MillsS.L., MaceyD.J., Mc GahanJ.P., MillerC.H., EpenetosA.Plot studies of radioimmuno therapy of B-cell lymphoma and leukemia using I131 Lym-1 monoclonal antibody.Antibody Immunoconjugates and Radiopharmaceuticals1988; 1: 17–33.
6.
BrittonK.E., MatherS.J., GranowskaM.Radiolabelled monoclonal antibodies in oncology III. Radioimmunotherapy.Nucl Med Commun1991; 12: 333–47.
7.
EpenetosA.A., HookerP.G., KrauszT., SnookD., BodmerW., Taylor-PapadimitriouJ.Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutical method possessing specificity against cancer cells.Obstet Gynecol,1986; 68: 71–4.
8.
HirdV., SnookC., KosmasB., DhokiaS., StewartP., MasonJ., LambertC., MearesC., EpenetosA.Intraperitoneal radioimmunotherapy with yttrium-90-labelled immunoconjugates. In: EpenetosA., ed. Monoclonal antibodies application in oncology.London: Chapman and Hall1991; 267–71.
9.
RivaP., MarangoloM., LazzariS., AgostiniM., SartiG., MoscatelliG., FranceschiG., SpinelliA., VecchiettiG.Locoregional immunotherapy of human ovarian cancer: preliminary results.Nucl Med Biol1989; 16: 659–66.
10.
RivaP., MarangoloM., TisonV., ArmaroliL., MoscatelliG., FranceschiG., SpinelliA., VecchiettiG., MorigiP., TassiniR., RivaN., TirindelliD.Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with Iodine-I131: a phase II study.Nucl Med Biol1991; 18: 109–19.
11.
SiccardiA.G., BuraggiG.L., CallegaroL.Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab’)2 fragments of anticarcinoembryonic antigen monoclonal antibody: a multicenter study.Cancer Research1989; 49: 3095–103.
12.
EpenetosA.A., BrittonK.E., MatherJ.: Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.Lancet1982; 2: 999–1004.
13.
ThorA., GosteinF., OhuchiN., SzpakC.A., JohnstonW.W., SchlomJ.Tumor-associated glycoprotein (TAG 72.3) in ovarian carcinomas defined by monoclonal antibody B 72.3.J Nat Cancer Inst1986; 76: 995–9.
14.
BossletK., KernH.F., KanzyE.J., SteinstrasserA., SchwarzA., LubenE., SchorlemmerH.U., SedlazekH.H.A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells.Cancer Immunol Immunother1986; 23: 185–9.
